These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31355513)

  • 1. Cardiologist as a cardiometabolic specialist.
    Katsi V; Andrikou I; Tsioufis C; Tousoulis D
    J Clin Hypertens (Greenwich); 2019 Sep; 21(9):1432-1435. PubMed ID: 31355513
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice.
    Slater TA; Drozd M; Palin V; Bowles C; Waduud MA; Khatib R; Ajjan RA; Wheatcroft SB
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):194-196. PubMed ID: 31702003
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2.
    Rodbard HW; Giaccari A; Cariou B; Garg S; Davies MJ; Seth K; Sawhney S
    Diab Vasc Dis Res; 2021; 18(1):1479164121995928. PubMed ID: 33611925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus.
    Papazafiropoulou AK; Mpoumi L; Papantoniou S; Rallatou M; Antonopoulos S; Melidonis A
    Ann Afr Med; 2021; 20(2):154-155. PubMed ID: 34213486
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiometabolic University 2017: Meeting Review and Presentation Summaries.
    Rengarajan R
    Rev Cardiovasc Med; 2018 Mar; 19(1):27-31. PubMed ID: 31032600
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetes drugs ride a bumpy road.
    Ledford H
    Nature; 2013 Dec; 504(7479):198. PubMed ID: 24336264
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood pressure control and components of the metabolic syndrome: the GOOD survey.
    Zidek W; Naditch-Brûlé L; Perlini S; Farsang C; Kjeldsen SE
    Cardiovasc Diabetol; 2009 Sep; 8():51. PubMed ID: 19754934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age- and gender-specific awareness, treatment, and control of cardiovascular risk factors and subclinical vascular lesions in a founder population: the SardiNIA Study.
    Scuteri A; Najjar SS; Orru' M; Albai G; Strait J; Tarasov KV; Piras MG; Cao A; Schlessinger D; Uda M; Lakatta EG
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):532-41. PubMed ID: 19321325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
    Ferreira JP; Verma S; Fitchett D; Ofstad AP; Lauer S; Zwiener I; George J; Wanner C; Zinman B; Inzucchi SE
    Cardiovasc Diabetol; 2020 Nov; 19(1):200. PubMed ID: 33243221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiologists' approach to managing cardiovascular risk in patients with type 2 diabetes.
    Rocha N; Das SR
    J Diabetes; 2019 Jul; 11(7):605-609. PubMed ID: 31044534
    [No Abstract]   [Full Text] [Related]  

  • 11. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
    Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
    Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic ketoacidosis with SGLT2 inhibitors.
    Musso G; Saba F; Cassader M; Gambino R
    BMJ; 2020 Nov; 371():m4147. PubMed ID: 33184044
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased burden and severity of metabolic syndrome and arterial stiffness in treatment-naïve HIV+ patients from Cameroon.
    Ngatchou W; Lemogoum D; Ndobo P; Yagnigni E; Tiogou E; Nga E; Kouanfack C; van de Borne P; Hermans MP
    Vasc Health Risk Manag; 2013; 9():509-16. PubMed ID: 24043942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of healthy vascular ageing in pooled population-based cohort studies: the global Metabolic syndrome and Artery REsearch Consortium.
    Nilsson PM; Laurent S; Cunha PG; Olsen MH; Rietzschel E; Franco OH; Ryliškytė L; Strazhesko I; Vlachopoulos C; Chen CH; Boutouyrie P; Cucca F; Lakatta EG; Scuteri A;
    J Hypertens; 2018 Dec; 36(12):2340-2349. PubMed ID: 30063641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs.
    Imprialos KP; Stavropoulos K; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):83-85. PubMed ID: 30009694
    [No Abstract]   [Full Text] [Related]  

  • 16. Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes.
    Miller EM; Wysham CH
    J Fam Pract; 2018 Aug; 67(8 suppl):S37-S42. PubMed ID: 30137052
    [No Abstract]   [Full Text] [Related]  

  • 17. Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects.
    Pioli MR; Ritter AMV; Modolo R
    Am J Hypertens; 2018 Feb; 31(3):274-280. PubMed ID: 29186300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
    Fadini GP; Frison V; Simioni N; Lapolla A; Gatti A; Bossi AC; Del Buono A; Fornengo P; Gottardo L; Laudato M; Perseghin G; Bonora E; Avogaro A
    J Am Heart Assoc; 2019 Jul; 8(14):e012244. PubMed ID: 31269877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in Asians and non-Asians.
    Fujita Y; Inagaki N
    J Diabetes Investig; 2019 Nov; 10(6):1408-1410. PubMed ID: 31541588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-Glucose Cotransporter 2 Inhibitors and Fournier Gangrene: A Rare and Lethal Adverse Event.
    O'Malley PA
    Clin Nurse Spec; 2019; 33(2):63-65. PubMed ID: 30730449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.